Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

NCT00815594 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Bleb Vascularity
Conjunctival Scarring

Interventions

DRUG: bevacizumab

Sponsor

Capital Medical University